Treatment Outcomes of HIV-Infected Adolescents Attending Public-Sector HIV Clinics Across Gauteng and Mpumalanga,South Africa

Abstract

There is little evidence comparing treatment outcomes between adolescents and other age groups, particularly in resource-limited settings. A retrospective analysis of data from seven HIV clinics across urban Gauteng (n=5) and rural Mpumalanga (n=2), South Africa was conducted. The analysis compared HIV-positive antiretroviral treatment (ART)-naive young adolescents (10–14 years), older adolescents (15–19), and young adults (20–24 years) to adults (≥25 years) initiated onto standard first-line ART between April 2004 and August 2010. Log-binomial regression was used to estimate relative risk (RR) of failure to suppress viral load (≥400 copies/ml) or failure to achieve an adequate CD4 response at 6 or 12 months. The effect of age group on virological failure, mortality, and loss to follow-up (LTFU; ≥90 days since scheduled visit date) was estimated using Cox proportional hazards models. Of 42,427 patients initiating ART, 310 (0.7%) were young adolescents, 342 (0.8%) were older adolescents, and 1599 (3.8%) were young adults. Adolescents were similar to adults in terms of proportion male, baseline CD4 count, hemoglobin, and TB. Compared to adults, both older adolescents (6 months RR 1.75 95% CI 1.25–2.47) and young adults (6 months RR 1.33 95% CI 1.10–1.60 and 12 months RR 1.64 95% CI 1.23–2.19) were more likely to have an unsuppressed viral load and were more likely to fail virologically (HR 2.90 95% CI 1.74–4.86; HR 2.94 95% CI 1.63–5.31). Among those that died or were LTFU, the median time from ART initiation until death or LTFU was 4.7 months (IQR 1.5–13.2) and 10.9 months (IQR 5.0–22.7), respectively. There was no difference in risk of mortality by age category, compared to adults. Young adolescents were less likely to be LTFU at any time period after ART initiation (HR 0.43 95% CI 0.26–0.69) whereas older adolescents and young adults were more likely to be LTFU after ART initiation (HR 1.78 95% CI 1.34–2.36; HR 1.63 95% CI 1.41–1.89) compared to adults. HIV-infected adolescents and young adults between 15 and 24 years have poorer ART treatment outcomes in terms of virological response, LTFU, and virological failure than adults receiving ART. Interventions are needed to help improve outcomes and retention in care in this unique population.

Get full access to this article

View all access options for this article.

References

World Health Organization: Towards Universal Access: Scaling up priority HIV/AIDS interventions in the Health SectorProgress Report April 2007WHO Press: Geneva, Switzerland, 2007.

Ryscavage

, Anderson

, Sutton

et al. Clinical outcomes of adolescents and young adults in adult HIV care. J Acquir Immune Defic Syndr, 2011; 58:193–197.

Agwu

, Rutstein

, Gaur

et al. and the HIV Research Network. Starting late, stopping early: Disparities in HAART utilization for behaviorally HIV-infected youth. 18th Conference on Retroviruses and Opportunistic Infections, BostonAbstract 692.

Nachega

, Hislop

, Nguyen

et al. Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. J Acquir Immune Defic Syndr, 2009; 51,1:65–71.

Nglazi

, Kranzer

, Holele

et al. Treatment outcomes in HIV-infected adolescents attending a community-based antiretroviral therapy clinic in South Africa. BMC Infect Dis, 2012; 12:21.

Bakanda

, Birungi

, Mwesigwa

et al. Survival of HIV-infected adolescents on antiretroviral therapy in Uganda: Findings from a nationally representative cohort in Uganda. PLoS One, 2011; 6,4:e19261.

National Department of Health, Republic of South Africa. The South African national antiretroviral treatment guidelines. 2004. http://southafrica.usembassy.gov/media/2004-dohart-guidelines.pdf. 2013 January 21.

National Department of Health, Republic of South Africa. The South African national antiretroviral treatment guidelines. 2010. www.fidssa.co.za/Guidelines/2010_Adult_ART_Guidelines.pdf. 2013 January 21.

Fox

, Maskew

, MacPhail

, Long

, Brennan

, Westreich

, MacLeod

, Majuba

, Sanne

. Cohort profile: The Themba Lethu Clinical Cohort, Johannesburg, South Africa. Int J Epidemiol, 2012; 10:1–10.

10.

UNICEF/WHO 1995: A picture of health—a review of and annotated bibliography of health of young people in developing countries. UNICEF New York. WHO: Geneva.

11.

Maskew

, Mahlangeni

, Fox

et al. Short-, long-term effect of Kaposi sarcoma on the response to HAART in the setting of the South African HIV epidemic. 17th Conference on Retroviruses and Opportunistic Infections, February 16–19, 2010, San Francisco, CaliforniaAbstract 763.

12.

Fox

, Brennan

, Maskew

et al. Using vital registration data to update mortality among patients loss to follow-up from ART programmes: Evidence from the Themba Lethu Clinic, South Africa. Trop Med Int Health, 2010; 15:405–413.

13.

Evans

, Maskew

, Sanne

. Increased risk of mortality and loss to follow-up among HIV positive patients with oropharyngeal candidiasis and malnutrition before antiretroviral therapy initiation: A retrospective analysis from a large urban cohort in Johannesburg, South Africa. Oral Med, 2012; 113:362–372.

14.

Brennan

, Maskew

, Sanne

et al. The importance of clinic attendance in the first six months on antiretroviral treatment: A retrospective analysis at a large public sector HIV clinic in South Africa. J Int AIDS Soc, 2010; 13:49.

15.

Maskew

, MacPhail

, Sanne

et al. Prevalence and effect of KSHV seropositivity on immunologic and virologic outcomes among HIV-infected adults initiating HAART in Johannesburg, South Africa. 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2011Abstract 874.

16.

Meya

, Spacek

, Tibenderana

et al. Development and evaluation of a clinical algorithm to monitor patients on antiretrovirals in resource-limited settings using adherence, clinical and CD4 cell count criteria. J Int AIDS Soc, 2009; 12,3 10.1186/1758-2652-12-3.

17.

Robbins

, Johnson

, Chang

et al. Predicting virological failure in an HIV clinic. Clin Infect Dis, 2010; 50:779–786.

18.

Sanne

, Orrell

, Fox

et al. and the CIPRA-SA Study Team. Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): A randomised non-inferiority trial. Lancet, 2010; 376:33–40.

19.

Westreich

, Evans

, Firnhaber

et al. Prevalent pregnancy, biological sex and virologic response to antiretroviral therapy. J Acquir Immune Defic Syndr, 2012; 60:489–494.

20.

Fairall

, Bachmann

, Louwagie

et al. Effectiveness of antiretroviral treatment in a South African program: A cohort study. Arch Intern Med, 2008; 168:86–93.

21.

Boulle

, Van Cutsem

, Hilderbrand

et al. Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS, 2010; 24:563–572.

22.

World Health Organization: WHO Child Growth Standards. Methods, development: Length/height-for-age, weight-for-age, weight-for-length, weight-for-height, body mass index-for-age. WHO Press: Geneva, Switzerland, 2006.

23.

Macdonald

, Maskew

, Evans

et al. HAART alone is not enough to deal with pediatric HIV: Treatment outcomes from a resource-limited setting in South Africa. Vulnerable Child Youth Studies, 2011; 6:208–221.

24.

May

, Boulle

, Phiri

et al. Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: A collaborative analysis of scale-up programs. Lancet, 2010; 376:449–457.

25.

Kigozi

, Dobkin

, Martin

et al. Late disease stage at presentation to an HIV clinic in the era of free antiretroviral therapy in sub-Saharan Africa. J Acquir Immune Defic Syndr, 2009; 52:280.

26.

Wilson

, Wright

, Safrit

et al. Epidemiology of HIV infection and risk in adolescents and youth. J Acquir Immune Defic Syndr, 2010; 54:S5–S6.

27.

Hunt

, Deeks

, Rodriguez

et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS, 2003; 17:1907–1915.

28.

Flynn

, Rudy

, Douglas

et al. Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy. J Infect Dis, 2004; 190:271–279.

29.

Flynn

, Rudy

, Lindsey

et al. Long-term observation of adolescents initiating HAART therapy: Three-year follow-up. AIDS Res Hum Retroviruses, 2007; 23:1208–1214.

30.

Murphy

, Belzer

, Durako

et al. Longitudinal antiretroviral adherence among adolescents infected with human immunodeficiency virus. Arch Pediatr Adolesc Med, 2005; 159:764–770.

31.

Khan

, Song

, Williams

et al. Evaluating adherence to medication in children and adolescents with HIV. Arch Dis Child, 2009; 94:970–973.

32.

Gross

, Zhang

, Grossberg

. Medications refill logistics and refill adherence in HIV. Pharmacoepidemiol Drug Saf, 2005; 14:789–793.

33.

Van Rossum

, Bergshoeff

, Fraaij

et al. Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children. Pediatr Infect Dis J, 2002; 21:473–747.

34.

Bangsberg

, Hecht

, Charlebois

et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS, 2000; 14:357–366.

35.

Van Dyke

, Lee

, Johnson

et al. Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection. Pediatrics, 2002; 109:e61.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.04 MB